- Home
- RLAY vs BBNX Comparison
RLAY vs BBNX Comparison
Compare RLAY & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- BBNX
- Stock Information
- Founded
- RLAY 2015
- BBNX 2015
- Country
- RLAY United States
- BBNX United States
- Employees
- RLAY N/A
- BBNX N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- BBNX Medical/Dental Instruments
- Sector
- RLAY Health Care
- BBNX Health Care
- Exchange
- RLAY Nasdaq
- BBNX Nasdaq
- Market Cap
- RLAY 576.1M
- BBNX 649.9M
- IPO Year
- RLAY 2020
- BBNX 2025
- Fundamental
- Price
- RLAY $3.63
- BBNX $13.52
- Analyst Decision
- RLAY Strong Buy
- BBNX Strong Buy
- Analyst Count
- RLAY 11
- BBNX 10
- Target Price
- RLAY $18.40
- BBNX $25.20
- AVG Volume (30 Days)
- RLAY 1.6M
- BBNX 526.7K
- Earning Date
- RLAY 08-05-2025
- BBNX 07-29-2025
- Dividend Yield
- RLAY N/A
- BBNX N/A
- EPS Growth
- RLAY N/A
- BBNX N/A
- EPS
- RLAY N/A
- BBNX N/A
- Revenue
- RLAY $7,679,000.00
- BBNX $69,830,000.00
- Revenue This Year
- RLAY $14.31
- BBNX $32.79
- Revenue Next Year
- RLAY N/A
- BBNX $36.59
- P/E Ratio
- RLAY N/A
- BBNX N/A
- Revenue Growth
- RLAY N/A
- BBNX 38911.17
- 52 Week Low
- RLAY $1.78
- BBNX $8.89
- 52 Week High
- RLAY $10.72
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- RLAY 63.22
- BBNX N/A
- Support Level
- RLAY $3.10
- BBNX N/A
- Resistance Level
- RLAY $3.75
- BBNX N/A
- Average True Range (ATR)
- RLAY 0.23
- BBNX 0.00
- MACD
- RLAY 0.03
- BBNX 0.00
- Stochastic Oscillator
- RLAY 84.42
- BBNX 0.00
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.